Value Sense
RGEN
Repligen Corporation (RGEN)
Last Price$155.4(2.4%)
Market Cap$8,979.7M
LTM EBITDA
$87.3M
YoY Growth
-52.8%
3Y CAGR
-22.2%
5Y CAGR
+8.4%
Stock quality & Intrinsic value
6/10
80.8% overvalued
RGEN
is (80.8%) overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Repligen Corporation EBITDA

Annual
Quarterly
LTM
Crunching data... Almost there!
Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
EBITDA
($2,227.3K)
($1,220.0K)
($1,825.0K)
$36.7M
$6,853.0K
($3,517.6K)
$1,657.2K
($30.5K)
$14.8M
$26.1M
$15.2M
$22.4M
$24.6M
$24.1M
$41.8M
$58.4M
$101.6M
$211.6M
$246.9M
$127.8M
RGEN
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for RGEN and see if it's the right time to invest.
Dive in

Repligen Corporation (RGEN) EBITDA comparison analysis

General

LTM EBITDA

Growth

Company name

YoY growth

3Y CAGR

5Y CAGR

Repligen Corporation logo
Repligen CorporationRGEN
$87.3M
(52.8%)
(22.2%)
8.4%
Median Peer Set
$1,115.5M
6.9%
1.0%
8.5%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$3,684.0M
(11.2%)
(6.7%)
0.1%
Intuitive Surgical, Inc. logo
Intuitive Surgical, Inc.ISRG
$2,761.1M
27.3%
11.9%
11.8%
Alcon Inc. logo
Alcon Inc.ALC
$2,035.2M
(9.3%)
5.5%
11.5%
ResMed Inc. logo
ResMed Inc.RMD
$1,656.1M
17.1%
12.4%
15.7%
Hologic, Inc. logo
Hologic, Inc.HOLX
$1,220.3M
14.8%
(22.8%)
20.8%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$1,010.7M
15.7%
1.9%
4.1%
Baxter International Inc. logo
Baxter International Inc.BAX
$952.0M
(48.3%)
(31.6%)
(10.6%)
AptarGroup, Inc. logo
AptarGroup, Inc.ATR
$754.8M
13.7%
8.8%
5.6%
West Pharmaceutical Services, Inc. logo
West Pharmaceutical Services, Inc.WST
$739.8M
(12.8%)
(5.9%)
13.1%
Masimo Corporation logo
Masimo CorporationMASI
($201.4M)
N/A
N/A
N/A

RGEN key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Revenue
% growth
6.9
0.0%
9.4
35.4%
12.9
37.9%
14.1
9.0%
19.3
37.1%
29.4
52.2%
21.0
(28.6%)
27.3
30.1%
62.3
128.2%
68.2
9.5%
63.5
(6.8%)
83.5
31.5%
104.5
25.1%
141.2
35.1%
194.0
37.4%
270.2
39.3%
366.3
35.5%
670.5
83.1%
801.5
19.5%
632.4
(21.1%)
Cost of Goods Sold (COGS)3.23.93.63.66.26.85.57.127.225.228.035.347.167.186.0119.1156.6279.3345.8323.5
Gross Profit
% margin
3.7
53.0%
5.5
58.5%
9.4
72.5%
10.5
74.3%
13.1
68.1%
22.6
76.9%
15.5
73.7%
20.2
73.9%
35.1
56.4%
43.0
63.1%
35.5
55.9%
48.3
57.8%
57.4
54.9%
74.2
52.5%
108.1
55.7%
151.1
55.9%
209.6
57.2%
391.3
58.3%
455.7
56.9%
308.8
48.8%
Operating Expenses13.69.610.612.3(22.8)18.721.220.523.720.022.830.438.260.282.1115.1139.8218.1259.8261.1
Research & Development Expenses (R&D)6.55.05.25.97.212.814.212.510.57.35.65.77.48.715.819.520.234.343.942.7
Selling, General & Administrative Expenses (SG&A)4.74.65.46.410.25.97.18.013.212.717.224.730.951.566.395.6119.6183.9215.8216.9
Operating Income
% margin
(9.9)
(143.8%)
(4.2)
(44.5%)
(1.2)
(9.4%)
(1.8)
(13.0%)
35.9
186.0%
3.9
13.2%
(5.8)
(27.5%)
(0.4)
(1.4%)
11.1
17.8%
22.9
33.6%
10.7
16.8%
13.8
16.5%
16.0
15.3%
14.0
9.9%
26.0
13.4%
14.9
5.5%
42.5
11.6%
133.5
19.9%
133.6
16.7%
47.7
7.5%
Interest Income0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.05.31.70.27.00.0
Interest Expense0.00.00.70.00.00.00.00.00.10.00.00.03.86.46.79.312.112.71.210.0
Pre-tax Income(9.6)(3.0)0.7(0.9)37.95.8(4.9)(0.0)11.323.011.113.411.77.221.426.259.2153.5219.156.7
Income Tax
% effective tax rate
9.6
(100.0%)
3.0
(100.0%)
(0.7)
(100.0%)
0.9
(100.0%)
0.8
2.2%
0.0
0.5%
(0.8)
17.0%
(0.3)
759.8%
(2.9)
(25.6%)
6.9
30.1%
3.0
26.6%
4.1
30.4%
0.0
0.1%
(21.1)
(291.2%)
4.8
22.5%
4.7
18.1%
(0.7)
(1.2%)
25.3
16.4%
33.2
15.1%
21.1
37.2%
Net Income
% margin
(9.6)
(138.1%)
(3.0)
(31.9%)
0.7
5.4%
(0.9)
(6.3%)
37.1
192.3%
5.7
19.6%
(4.1)
(19.4%)
(0.0)
(0.2%)
14.2
22.7%
16.1
23.6%
8.2
12.9%
9.3
11.2%
11.7
11.2%
28.4
20.1%
16.6
8.6%
21.4
7.9%
59.9
16.4%
128.3
19.1%
186.0
23.2%
35.6
5.6%
EPS(0.32)(0.10)0.02(0.03)1.200.19(0.13)(0.00)0.460.510.250.280.350.740.380.441.142.333.350.64
Diluted EPS(0.32)(0.10)0.02(0.03)1.180.18(0.13)(0.00)0.450.500.250.280.340.720.370.441.112.243.240.63
EBITDA
% margin
(2.2)
(32.2%)
(1.2)
(13.0%)
(1.8)
(14.1%)
36.7
260.9%
6.9
35.5%
(3.5)
(12.0%)
1.7
7.9%
(0.0)
(0.1%)
14.8
23.8%
26.1
38.3%
15.2
23.9%
22.4
26.9%
24.6
23.5%
24.1
17.1%
41.8
21.5%
58.4
21.6%
101.6
27.7%
211.6
31.6%
246.9
30.8%
127.8
20.2%

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Repligen Corporation's EBITDA?

As of today, Repligen Corporation's last 12-month EBITDA is $87.3M, based on the financial report for Sep 30, 2024 (Q3’2024).

2) What is Repligen Corporation's EBITDA growth rate?

Over the last year, Repligen Corporation's EBITDA growth was (52.8%). The average annual EBITDA growth rates for Repligen Corporation have been (12.0%) over the past three years, 8.4% over the past five years.

4) How does Repligen Corporation's EBITDA growth rate compare to its peers?

Over the last year, Repligen Corporation's EBITDA growth was (52.8%), which is lower than peer median growth of (10.0%). The list of peers includes BDX, ISRG, ALC, RMD, HOLX, COO, BAX, ATR, WST, MASI etc.